Prevention of bleeding in hemophilia patients with high-titer inhibitors

Show simple item record

dc.contributor.author Leissinger, Cindy A.
dc.contributor.author Konkle, Barbara A.
dc.contributor.author Antunes, Sandra V. [UNIFESP]
dc.date.accessioned 2016-01-24T14:40:34Z
dc.date.available 2016-01-24T14:40:34Z
dc.date.issued 2015-06-01
dc.identifier http://dx.doi.org/10.1586/17474086.2015.1036733
dc.identifier.citation Expert Review of Hematology. London: Expert Reviews, v. 8, n. 3, p. 375-382, 2015.
dc.identifier.issn 1747-4086
dc.identifier.uri http://repositorio.unifesp.br/handle/11600/39140
dc.description.abstract Inhibitor development is the most serious adverse event linked to the treatment of hemophilia, as it renders standard hemostatic therapy ineffective. Consequently, inhibitor patients are at increased risk for difficult-to-control bleeding and complications, particularly arthropathy and physical disability. Three randomized clinical trials in patients with inhibitors have demonstrated that compared with on-demand bypassing therapy, prophylaxis with a bypassing agent reduces joint and other types of bleeding and improves health-related quality of life. in hemophilia patients without inhibitors, the initiation of prophylaxis with factor (F) VIII or IX prior to the onset of recurrent hemarthroses can prevent the development of joint disease. Whether this is also true for bypassing agent prophylaxis remains to be determined. en
dc.description.sponsorship Baxter
dc.description.sponsorship Bayer
dc.description.sponsorship CSL Behring
dc.description.sponsorship Novo Nordisk
dc.description.sponsorship Baxter Healthcare Corp
dc.format.extent 375-382
dc.language.iso eng
dc.publisher Expert Reviews
dc.relation.ispartof Expert Review of Hematology
dc.rights Acesso restrito
dc.subject activated prothrombin complex concentrate en
dc.subject bypassing agents en
dc.subject factor IX en
dc.subject factor VIII en
dc.subject hemophilia A en
dc.subject hemophilia B en
dc.subject inhibitors en
dc.subject prophylaxis en
dc.subject recombinant activated factor VII en
dc.title Prevention of bleeding in hemophilia patients with high-titer inhibitors en
dc.type Resenha
dc.contributor.institution Tulane Univ
dc.contributor.institution Blood Works NW
dc.contributor.institution Univ Washington
dc.contributor.institution Universidade Federal de São Paulo (UNIFESP)
dc.description.affiliation Tulane Univ, Med Ctr, Louisiana Ctr Bleeding & Clotting Disorders, New Orleans, LA 70118 USA
dc.description.affiliation Blood Works NW, Seattle, WA USA
dc.description.affiliation Univ Washington, Seattle, WA 98195 USA
dc.description.affiliation Universidade Federal de São Paulo, São Paulo, Brazil
dc.description.affiliationUnifesp Universidade Federal de São Paulo, São Paulo, Brazil
dc.identifier.doi 10.1586/17474086.2015.1036733
dc.description.source Web of Science
dc.identifier.wos WOS:000354389000013



File

File Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

Search


Browse

Statistics

My Account